Myelodysplastic syndrome : nature.com subject feeds
RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis
Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients
Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies
Cut-like homeobox 1 (CUX1) tumor suppressor gene haploinsufficiency induces apoptosis evasion to sustain myeloid leukemia
Successful rescue transplant for children with primary graft failure using early intervention with a single day preparative regimen and related haploidentical donor
Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition
Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway
Outcomes of pediatric patients who relapse after first HCT for acute leukemia or MDS
Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression
Chronic myelomonocytic leukemia diagnosis and management
CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes
Pretransplant increasing rate of lactate dehydrogenase as a predictor of transplant outcomes for patients with myeloid hematological malignancies
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia
Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study
Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease
The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms
Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
Long non-coding RNAs as novel therapeutic targets in juvenile myelomonocytic leukemia
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report
Germline variants drive myelodysplastic syndrome in young adults
Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant£
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
Molecular-Based Score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome
Overexpression of Hmga2 activates Igf2bp2 and remodels transcriptional program of Tet2-deficient stem cells in myeloid transformation
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms
Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points
Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia
Genome-wide methylation sequencing identifies progression-related epigenetic drivers in myelodysplastic syndromes
Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant£
Feed Fetched by RSS Dog.